Uptravi Tablet, Film Coated
NDC Package 66215-910-14

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Uptravi (selexipag) tablets is selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). This formulation utilizes a tablet, film coated delivery system. Marketed by Actelion Pharmaceuticals Us, Inc., this product is identified by NDC 66215-910 and is authorized under FDA application NDA207947.

Identification & Billing

NDC Package Code
66215-910-14
Package Description
1 BOTTLE in 1 CARTON / 140 TABLET, FILM COATED in 1 BOTTLE
Product Code
66215-910
11-Digit Billing Format
66215091014
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Uptravi
Non-Proprietary Name
Selexipag
Substance Name
Selexipag
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
SELEXIPAG 100 ug/1
Pharmacologic Class
Usage Information
Selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). It is used to help slow down worsening of PAH and to decrease the chance of needing treatment in a hospital. Selexipag works by making it easier for blood to flow through the arteries in your lungs. This effect helps increase your ability to exercise.

Regulatory & Marketing

Labeler Name
Actelion Pharmaceuticals Us, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA207947
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-23-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66215-910-14 identifies a specific commercial package of 1 bottle in 1 carton / 140 tablet, film coated in 1 bottle of Uptravi, a human prescription drug labeled by Actelion Pharmaceuticals Us, Inc.. This tablet, film coated is formulated for oral use and contains selexipag as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Actelion Pharmaceuticals Us, Inc. on May 23, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). It is used to help slow down worsening of PAH and to decrease the chance of needing treatment in a hospital. Selexipag works by making it easier for blood to flow through the arteries in your lungs. This effect helps increase your ability to exercise.

How is this Actelion Pharmaceuticals Us, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66215091014. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
66215-910-14
11-Digit CMS (5-4-2)
66215-0910-14

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.